Nicorette

Nicorette is a global brand of nicotine-replacement therapy products used to relieve cravings and withdrawal symptoms associated with stopping or reducing tobacco and, in some markets, nicotine use. Its principal formats include nicotine gum, lozenges, transdermal patches, mouth spray, sublingual tablets, inhalators, and nasal spray. The products generally contain nicotine polacrilex or another controlled-release nicotine formulation and are intended to be used alongside behavioral support or a structured quit plan. The brand originated in Sweden through AB Leo, where researcher Ove Fernö and colleagues developed a way to deliver nicotine through chewing gum. The key technical advance was binding nicotine to an ion-exchange resin, allowing nicotine to be released gradually as the gum was chewed. Early research was conducted with Lund University clinicians, and findings were presented at international tobacco-control and smoking-health conferences during the 1970s. Nicorette was registered as a medicine in Switzerland in 1978, Canada in 1979, the United Kingdom in 1980, and Sweden in 1981. The United States Food and Drug Administration approved Nicorette gum in 1984 after a lengthy review, with Marion Merrell Dow introducing it under licence. Nicorette was the first widely marketed nicotine-replacement product and helped establish NRT as a pharmaceutical approach to smoking cessation. Its portfolio subsequently expanded beyond gum. A nicotine patch was introduced in 1991, nasal spray in 1994, an inhaler in 1996, and Microtab sublingual tablets in 1999. Lozenges, coated gums, flavored products, more discreet patches, and QuickMist oral spray broadened the brand's delivery options and addressed different patterns of dependence and consumer preferences. Medical guidance for Nicorette varies by product, country, age, pregnancy status, concurrent nicotine use, and underlying health conditions. Gum and lozenges release nicotine through the mouth, while patches provide slower transdermal delivery over part of the day. QuickMist is designed for faster oral absorption and has also been studied in people seeking to reduce urges to vape. Consumers are generally advised to follow the relevant label, avoid excessive dosing, and seek medical advice in situations such as pregnancy, cardiovascular symptoms, significant drug interactions, or suspected nicotine overdose. The brand has operated under changing corporate ownership. The original business became associated with Pharmacia and Upjohn, and later ownership structures placed Nicorette in the consumer-health portfolios now associated with Kenvue outside the United States and Haleon in the United States. In April 2024, nicotine gum and patch products manufactured by Kenvue and marketed under Nicorette in many countries became the first NRT products to receive World Health Organization prequalification, supporting procurement by international health organizations. Nicorette has also used public-facing campaigns, digital tools, product innovation, and sports sponsorship to position itself as a cessation aid rather than a tobacco product. Its communication has emphasized craving management, gradual dose reduction, discreet use, and behavioral support. The brand remains active internationally, although product availability, names, strengths, indications, and regulatory status differ between markets.

Nicorette emerged from Swedish pharmaceutical research into a practical substitute for tobacco-derived nicotine. In December 1967, Ove Fernö of AB Leo received a suggestion from physician Claes Lundgren that an orally consumed nicotine product could help people who could not smoke. Observations of submariners and aviation personnel switching to chewing tobacco or snus helped inspire the concept. Fernö began systematic experiments in 1969 and later stopped smoking himself after using the developing gum. AB Leo produced an early nicotine gum in 1971. Its distinctive technology combined nicotine with an ion-exchange resin, later described as nicotine polacrilex, to moderate release during chewing. This enabled nicotine to be absorbed through the oral mucosa rather than delivered by smoke. Håkan Westling and colleagues at Lund University began clinical work in the same period. Their findings, together with research by Fernö and later work involving British scientist Michael Russell, were presented at international conferences and published in the early 1970s. Regulatory adoption occurred progressively. Nicorette was registered in Switzerland in 1978, Canada in 1979, the United Kingdom in 1980, and Sweden in 1981. Swedish authorities initially hesitated because smoking was treated partly as a lifestyle choice and orally consumed nicotine was not immediately regarded as a medicine. In January 1984, the FDA approved Nicorette gum in the United States. The American launch was handled by Marion Merrell Dow under licence from AB Leo, helping establish the brand in the world's largest pharmaceutical market. The product family expanded through the 1990s and 2000s. A transdermal patch appeared in 1991, followed by nasal spray in 1994, an inhalator in 1996, and Microtab sublingual tablets in 1999. U.S. regulatory decisions also enabled broader over-the-counter access to Nicorette gum and nicotine patches in 1996, while nicotine lozenges received comparable nonprescription treatment in 2002. The brand introduced flavored and coated gums, including peppermint and fresh-mint variants, and later developed more discreet patch designs. QuickMist mouth spray, introduced in 2010, focused on faster relief of acute cravings. Digital support followed with the ActiveStop iOS application in 2011. Nicorette's market history has been shaped by changing medical and regulatory views about NRT. France removed cardiovascular and cerebrovascular disease contraindications for NRT in 2003, and the United Kingdom followed in 2005, reflecting the view that the benefits of replacing cigarette smoke could outweigh the risks of therapeutic nicotine for many smokers. UK guidance also expanded beyond immediate abstinence to include smoking reduction for people not yet ready to stop abruptly. In 2013, the FDA stated that continuing to smoke was no longer a formal contraindication to NRT use, although product labeling continued to advise consultation and caution in relevant circumstances. The portfolio has increasingly addressed different forms of nicotine dependence. Coated lozenges and flavored gums offered alternatives to traditional gum, while QuickMist has been evaluated for urges associated with vaping. In 2024, the WHO issued its first adult tobacco-cessation clinical guideline recommending pharmacotherapy, including NRT, alongside behavioral support. That year, Kenvue-made Nicorette gum and patch products received WHO prequalification, an important procurement milestone for global health programs. In 2025, Australia's TGA approved QuickMist for an indication specifically covering nicotine vaping dependence. Corporate ownership evolved from AB Leo through later pharmaceutical combinations including Pharmacia and Upjohn. Nicorette is now associated with Kenvue's consumer-health business outside the United States and Haleon's consumer-health business in the United States. The brand remains active, but its exact product formats, strengths, medical indications, and ownership presentation vary by jurisdiction.

• 2025

  Australian vaping-dependence indication

  [1]Nicoretteen.wikipedia.org

  Australia's TGA approved QuickMist as a registered medicine specifically indicated for nicotine vaping dependence.

• 2024

  WHO prequalification

  [1]Nicoretteen.wikipedia.org

  Kenvue-manufactured Nicorette gum and patches became the first NRT products to receive WHO prequalification.

• 2010

  QuickMist launched

  [1]Nicoretteen.wikipedia.org

  Nicorette introduced a 1 mg mouth spray intended to provide faster nicotine absorption than gum or lozenges.

• 2002

  U.S. lozenge access expands

  [1]Nicoretteen.wikipedia.org

  The FDA changed the status of Commit nicotine lozenges to over the counter in the United States.

• 1999

  Microtab introduced

  [1]Nicoretteen.wikipedia.org

  Nicorette expanded into sublingual nicotine tablets marketed as Microtab.

• 1996

  Inhalator launched and U.S. OTC access expanded

  [1]Nicoretteen.wikipedia.org

  Nicorette introduced an inhalator, while U.S. regulators approved over-the-counter status for Nicorette gum and the NicoDerm CQ patch.

• 1994

  Nasal spray introduced

  [1]Nicoretteen.wikipedia.org

  Nicorette added a nasal-spray delivery format.

• 1991

  Nicorette Patch introduced

  [1]Nicoretteen.wikipedia.org

  The brand expanded into transdermal nicotine replacement with its patch product.

• 1984

  U.S. FDA approval

  [1]Nicoretteen.wikipedia.org

  The FDA approved Nicorette gum for the United States after an extended review.

• 1981

  Swedish registration

  [1]Nicoretteen.wikipedia.org

  Nicorette received registration in its country of development, Sweden.

• 1980

  United Kingdom registration

  [1]Nicoretteen.wikipedia.org

  Nicorette was registered as a medicine in the United Kingdom.

• 1979

  Canadian registration

  [1]Nicoretteen.wikipedia.org

  Nicorette received Canadian registration.

• 1978

  First national registration

  [1]Nicoretteen.wikipedia.org

  Nicorette was registered as a medicine in Switzerland.

• 1973

  Early clinical findings published

  [1]Nicoretteen.wikipedia.org

  Clinical and pharmacological research on nicotine gum was presented and published, supporting its development as a cessation aid.

• 1971

  First nicotine gum produced

  [1]Nicoretteen.wikipedia.org

  AB Leo produced an early nicotine gum using ion-exchange resin technology to regulate nicotine release during chewing.

• 1969

  Nicotine gum experiments begin

  [1]Nicoretteen.wikipedia.org

  Fernö began experimenting with nicotine gum, using controlled release as the central technical objective.

• 1967

  Oral nicotine substitute proposed

  [1]Nicoretteen.wikipedia.org

  A suggestion from physician Claes Lundgren prompted AB Leo researcher Ove Fernö to investigate an orally consumed substitute for tobacco.

An over-the-counter nicotine-replacement brand positioned as a medically regulated aid for managing nicotine cravings and withdrawal during smoking cessation or smoking reduction.

• Nicotine chewing gum · 1971

  Nicorette Gum

  Nicorette gum releases nicotine as it is chewed slowly and intermittently. Nicotine is absorbed through the lining of the mouth, providing a user-controlled response to cravings. Common strengths include 2 mg and 4 mg, with selection depending on nicotine dependence and local labeling. The format is designed for episodic cravings and can be used within either an abrupt-cessation or smoking-reduction program where permitted.

• Nicotine lozenge

  Nicorette Lozenges

  Nicorette lozenges dissolve in the mouth and release nicotine without requiring chewing. They offer a discreet alternative to gum and are intended to manage acute cravings and withdrawal symptoms. Coated and flavored variants, including mint-oriented products, have been introduced in some markets. Availability, dose strengths, and instructions differ by country.

• Transdermal nicotine patch · 1991

  Nicorette Patch

  Nicorette patches provide a relatively steady supply of nicotine through the skin over part of the day. Step-down regimens use higher strengths at the beginning of a quit program and lower strengths later. The brand has offered both conventional and more discreet semi-transparent designs, with local products differing in wear time, dosage, and appearance.

• Nicotine oral spray · 2010

  Nicorette QuickMist

  QuickMist is a nicotine mouth spray designed for rapid delivery during an episode of craving. In some markets it can connect with a smartphone application through near-field communication to track doses and provide behavioral support. Clinical research has examined its ability to reduce urges among exclusive e-cigarette users, and Australian regulators approved a vaping-dependence indication in 2025.

• Sublingual nicotine tablet · 1999

  Nicorette Microtab

  Microtab tablets are placed under the tongue and allowed to dissolve gradually rather than being chewed. The delivery method is intended to provide an alternative to gum and is used in some markets for smoking cessation or reduction. Recommended daily amounts and maximum doses are determined by local regulatory labeling.

• Nicotine inhalation device · 1996

  Nicorette Inhalator

  The inhalator provides nicotine through a mouthpiece and may appeal to smokers who value a hand-to-mouth ritual. It is a non-combustible pharmaceutical delivery format, not a tobacco product. Its availability and instructions vary across markets.

• Nicotine nasal spray · 1994

  Nicorette Nasal Spray

  Nicorette's nasal spray is another rapid-delivery NRT format intended for managing strong cravings. It was introduced during the brand's 1990s expansion beyond gum and patches. Current availability is market-specific.

• 2011ActiveStop

  United Kingdom

  Nicorette UK launched an iOS application offering quit targets, information, games, distractions, and achievement sharing. The initiative extended the brand from a medicine supplier into a digitally supported cessation program.

  Outcome. The app provided digital behavioral-support features for people attempting to stop smoking.

  Source
• 1993Nicorette yacht-racing sponsorship

  International

  Nicorette began sponsoring yacht racing in association with sailor Ludde Ingvall and a non-smoking sailing team. The sponsorship presented the brand as aligned with a tobacco-free, health-oriented sporting identity.

  Outcome. The branded yacht became associated with several major offshore-racing performances and records.

  Source

• 2025

  Extend QuickMist to vaping dependenceProduct launch

  Background

  The growth of e-cigarette use created demand for treatments addressing nicotine cravings that are not limited to combustible-cigarette cessation.

  Action taken

  Australia's TGA approved Nicorette QuickMist as a registered medicine specifically indicated for nicotine vaping dependence.

  Aftermath

  QuickMist became an early regulated product with an explicit vaping-dependence indication in Australia.

  Source

• 2024

  Support international procurement through WHO prequalificationStrategy

  Background

  WHO prequalification allows eligible health organizations and programs to assess and procure certain medicines for global public-health use.

  Action taken

  Kenvue-manufactured Nicorette gum and patch products received WHO prequalification.

  Aftermath

  The products became the first nicotine-replacement therapies to receive WHO prequalification, strengthening their potential role in international cessation programs.

  Source

• 2010

  Introduce rapid-delivery mouth sprayProduct launch

  Background

  Gum and lozenges require time for nicotine release, creating demand for a faster response to cravings.

  Action taken

  Nicorette launched QuickMist mouth spray.

  Aftermath

  The portfolio gained a rapid-delivery format later studied for both smoking and vaping urges.

  Source

• 1991

  Add transdermal nicotine deliveryProduct launch

  Background

  A patch format could provide slower, steadier nicotine delivery than an as-needed oral product.

  Action taken

  Nicorette introduced its nicotine patch.

  Aftermath

  The brand broadened its appeal to consumers seeking continuous nicotine replacement during the day.

  Source

• 1984

  Enter the U.S. consumer-health marketStrategy

  Background

  FDA approval created a route for nicotine gum to be sold in the United States as a regulated cessation medicine.

  Action taken

  Marion Merrell Dow introduced Nicorette gum under licence from AB Leo.

  Aftermath

  The U.S. launch helped establish Nicorette as an international NRT brand.

  Source

1. 1Nicoretteen.wikipedia.org